The survival outcomes of the FLAURA trial support osimertinib as the new first-line standard of care for patients with EGFR-mutated advanced-stage non-small-cell lung cancer in health-care systems that can afford its cost. However, the low crossover rate is a flaw of this study. Knowledge of mechanisms of resistance to provide tailored treatment is the new challenge preventing a continued paradigm shift in this disease.

中文翻译：

---

前期奥西替尼-赢家能承担全部费用吗？

FLAURA试验的生存结果支持osimertinib作为在医疗保健系统中负担得起其费用的EGFR突变晚期非小细胞肺癌患者的新一线治疗标准。但是，低交叉率是这项研究的缺陷。提供针对性治疗的耐药机制的知识是防止这种疾病继续发生范式转移的新挑战。